



**CONTACT:**

**Julia A. Dishman (617) 441-1000**

**FOR IMMEDIATE RELEASE**

**MERRIMACK PHARMACEUTICALS WELCOMES GARY L. CROCKER  
TO THE BOARD OF DIRECTORS**

**CAMBRIDGE, MA, May 4, 2004** – Merrimack Pharmaceuticals, Inc. today announced that Gary L. Crocker has joined the company's board of directors. Mr. Crocker has more than 20 years of experience growing companies in the biotechnology and medical device industries, and is currently the President of Crocker Ventures, LLC, a life sciences focused private investment firm. He also currently serves on the Advisory Board of Sorenson Capital LLC, a late stage private investment firm.

Prior to the formation of Crocker Ventures, Mr. Crocker was the founder and President of Research Medical, a publicly held cardiac device manufacturer, which was acquired by Baxter International in 1997. Under the guidance of Mr. Crocker, Research Medical developed into the world's largest supplier of cardiac by-pass catheters. From 1998-2003, he served as chairman of the Board of ARUP, one of the nation's largest esoteric diagnostic test laboratories. Mr. Crocker was also one of the original investing directors in Salt Lake City-based Theratech, Inc., and served on the Board of Directors from 1985 - 1999 when the firm was sold to Watson Pharmaceuticals. Prior to founding Research Medical in 1983, Mr. Crocker was Vice President of Business Development for Sorenson Research Division of Salt Lake City-based Abbott Laboratories. As such, Mr. Crocker was the lead negotiator when Abbott acquired Sorenson in 1981. Mr. Crocker earned a Masters of Business Administration and also graduated magna cum laude with a Bachelor of Science degree in Economics both from Harvard.

"We are very pleased to add Mr. Crocker's broad industry expertise to our board at this exciting time in Merrimack's development," stated Robert Mulroy, the President and CEO of Merrimack. "We are confident that Gary's participation on our Board, and the experience he brings through his many successes in guiding emerging life sciences businesses, will be invaluable as we continue to grow the company."

"I am honored and excited to join Merrimack's board," commented Gary Crocker. "The company has the capacity to make fundamental clinical contributions in the growing arenas of both autoimmune diseases and cancer as it moves forward with the clinical development of its lead product, MM-093, and continues to strengthen and expand its Network Biology™-based drug discovery capabilities."

Merrimack Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. Founded by leading scientists from MIT and Harvard, the company's proprietary Network Biology™ discovery platform enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is a privately held company based in Cambridge, Massachusetts. For additional information, please visit [www.merrimackpharma.com](http://www.merrimackpharma.com).